Parabilis Medicines, Inc.·4

Jun 15, 5:17 PM ET

Borisy Alexis 4

4 · Parabilis Medicines, Inc. · Filed Jun 15, 2026

Research Summary

AI-generated summary of this filing

Updated

Parabilis (PBLS) Director Alexis Borisy Acquires 267,635 Shares via Conversion

What Happened

  • Director Alexis Borisy reported conversion of derivative securities into common stock, receiving two allotments: 105,414 shares and 162,221 shares, for a total of 267,635 shares. The Form 4 lists the transaction code as C (conversion) and shows no purchase price (N/A), indicating shares were received by conversion rather than an open‑market purchase.

Key Details

  • Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the normal two-business-day window).
  • Shares received: 105,414 and 162,221 (total 267,635). Price per share: N/A; total dollar value: not reported.
  • Footnote: F1 — Each share of Series F Preferred was convertible into common stock on a 1 to 0.6498 basis and was automatically converted immediately prior to the issuer’s IPO closing on June 9, 2026. The Preferred Stock had no expiration date.
  • Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context

  • This was a conversion of preferred stock into common stock (not a cash purchase or sale). Per the footnote, the conversions were tied to the company’s IPO process (automatic conversion of Series F preferred into common immediately before the IPO). Conversions like this are typically routine corporate actions related to capitalization changes rather than directional insider buying or selling.

Insider Transaction Report

Form 4
Period: 2026-06-11
Transactions
  • Conversion

    Common Stock

    [F1]
    2026-06-11+105,414105,414 total
  • Conversion

    Series F Preferred Stock

    [F1]
    2026-06-11+162,2210 total
    Common Stock (105,414 underlying)
Footnotes (1)
  • [F1]Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.
Signature
/s/ Teresa Jurgensen, Attorney-in-Fact|2026-06-15

Documents

1 file
  • 4
    ownership.xmlPrimary

    4